See more : Quantum Medical Transport, Inc. (DRWN) Income Statement Analysis – Financial Results
Complete financial analysis of Blue Water Vaccines, Inc. (BWV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Blue Water Vaccines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DB Insurance Co., Ltd. (005830.KS) Income Statement Analysis – Financial Results
- Gowing Bros. Limited (GOW.AX) Income Statement Analysis – Financial Results
- MyState Limited (MYS.AX) Income Statement Analysis – Financial Results
- A.K. Spintex Limited (AKSPINTEX.BO) Income Statement Analysis – Financial Results
- IB Acquisition Corp. Common Stock (IBAC) Income Statement Analysis – Financial Results
Blue Water Vaccines, Inc. (BWV)
About Blue Water Vaccines, Inc.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.13M | 1.33M | 524.91K | 60.17K |
| General & Administrative | 9.35M | 2.09M | 1.10M | 820.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.35M | 2.09M | 1.10M | 820.06K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 3.42M | 1.62M | 880.23K |
| Cost & Expenses | 13.48M | 3.42M | 1.62M | 880.23K |
| Interest Income | 0.00 | 0.00 | 22.60K | 58.32K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -61.41K | 4.89K | 3.06K | 573.00 |
| EBITDA | -13.48M | -3.41M | -1.62M | -879.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -3.42M | -1.62M | -880.23K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 61.41K | 0.00 | 22.60K | 58.32K |
| Income Before Tax | -13.42M | -3.42M | -1.60M | -821.92K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -129.57K | 0.00 | -22.60K | -58.32K |
| Net Income | -13.29M | -3.42M | -1.58M | -763.60K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -0.31 | -0.14 | -0.07 |
| EPS Diluted | -1.08 | -0.31 | -0.14 | -0.07 |
| Weighted Avg Shares Out | 12.27M | 10.91M | 11.05M | 11.05M |
| Weighted Avg Shares Out (Dil) | 12.27M | 10.91M | 11.05M | 11.05M |
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement...
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today issued the following...
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
First state license is a key achievement as Blue Water continues to expand its business into commercial activities First state license is a key achievement as Blue Water continues to expand its business into commercial activities
Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs
Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that Blue Water management will present at the JMP Securities...
How to Trade Penny Stocks Online: Short Guide
Here's some tips on how to trade penny stocks online The post How to Trade Penny Stocks Online: Short Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy After CPI Report? 3 To Watch Today
Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco
CINCINNATI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at the...
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego,...
Source: https://incomestatements.info
Category: Stock Reports